EUCTR2004-004661-15-GB进行中（未招募）不适用
A Phase III Randomized Study of CLORETAZINE™ (VNP40101M) and Cytosine Arabinoside (AraC) in Patients with Acute Myeloid Leukemia in First Relapse
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 420
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •A.Patients must have AML (any WHO classification excluding acute promyelocytic leukemia) in first relapse after a first CR (or CRp) . Bone marrow aspirates and/or biopsies must contain = 10% blasts. The duration of first CR (or CRp) must have been at least 3 months but less than 24 months, calculated from the day CR was documented following the initial induction regimen to the day leukemia relapse was confirmed by recurrence of blasts in peripheral blood, bone marrow histopathology and/or histological proven CNS or extramedullary disease.
- •B.There is no restriction on number of regimens or type of treatment required to induce first CR (or CRp) or number of regimens or type of treatment administered for consolidation in first CR (or CRp).
- •C.Patients cannot have received any treatment other than hydroxyurea in first relapse. Hydroxyurea should be discontinued at least 12 hours prior to initiation of protocol treatment.
- •D.Age = 18.
- •E.ECOG performance status of 0-2.
- •F.Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must use acceptable contraceptive methods (abstinence, intrauterine device (IUD), oral contraceptive or double barrier device), and must have a negative serum or urine pregnancy test within 2 weeks prior to beginning treatment on this trial. Nursing patients are excluded. Sexually active men must also use acceptable contraceptive methods. Pregnant and nursing patients are excluded because the effects of CLORETAZINE™ on a fetus or nursing child are unknown.
- •G.Must be able and willing to give written informed consent and comply with requirements of the protocol.
- •H.Patients must have the following clinical laboratory values:
- •1.Serum creatinine £ 2.0 mg/dl.
- •2.Total bilirubin £ 1.5x the upper limit of normal.
- •3.Aspartate aminotransferase (AST, SGOT) £ 3x the upper limit of normal.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •A.Uncontrolled active infection of any kind. Patients with infections that are under active treatment with antibiotics and whose infections are controlled may be entered to the study. Patients with chronic hepatitis are eligible.
- •B.No current evidence of invasive fungal infection (blood cultures or tissues cultures). C.Myocardial infarction within previous 3 months, arrhythmias not controlled by medication, or uncontrolled congestive heart failure.
- •D.Patients receiving any other standard or investigational treatment for their leukemia.
- •E.Clinical evidence by tumor marker, pathology, or radiologic studies of an active second malignancy.
- •F.Presence of any other severe medical condition that may compromise the safety of treatment, for example, severe chronic obstructive pulmonary disease, or requirement for supplemental oxygen at rest.
- •G.Because the CLORETAZINE™ formulation contains 30% ethanol, patients being treated with disulfiram (Antabuse) are excluded from the study.
研究者
相似试验
进行中（未招募）
不适用
A Phase III Randomized Study of CLORETAZINE™ (VNP40101M) and Cytosine Arabinoside (AraC) in Patients with Acute Myeloid Leukemia in First RelapseEUCTR2004-004661-15-DEVion Pharmaceuticals, Inc.420
尚未招募
3 期
A research study for patients with acute myeloid leukemia (AML) in first relapseCancer - Leukaemia - Acute leukaemiaAcute Myeloid LeukemiaACTRN12606000514505Vion Pharmaceuticals, Inc.420
进行中（未招募）
不适用
A Phase 3 Randomized Trial of Concurrent Cisplatin And Radiotherapy With or Without OncoVEXGM-CSF in Previously Untreated Patients with Locally Advanced Squamous Cell Carcinoma of the Head and NeckEUCTR2010-019071-29-GBBioVex, Inc.580
进行中（未招募）
不适用
Multicenter phase III randomized study of cisplatin and etoposide with or without bevacizumab as first-line treatment in extensive stage (ED) small cell lung cancer (SCLC) - NDEUCTR2007-007949-13-ITGRUPPO ONCOLOGICO ITALIANO DI RICERCA
进行中（未招募）
1 期
A phase III, randomised study to evaluate the clinical consistency in terms of immunogenicity and reactogenicity of three production lots of the liquid formulation of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine and to evaluate the liquid formulation as compared to the lyophilised formulation of the HRV vaccine in terms of immunogenicity, reactogenicity and safety when administered as a two-dose primary vaccination in healthy infants previously uninfected with HRV. - rota-061Two-dose immunisation at 3 and 4 months of age in healthy infants previously uninfected with HRV.EUCTR2006-003239-61-FIGlaxoSmithKline Biologicals1,200